0001641489-26-000010
SEC filingvTv Therapeutics Inc. reported a net loss attributable to the company of $27.0 million for fiscal year 2025, driven by an operating loss of $32.8 million. The company generated no revenue during the period. Total operating expenses were $32.8 million, consisting of $17.9 million in research and development and $14.9 million in general and administrative expenses. The net loss per share was $3.00. The company ended the year with $88.9 million in cash and cash equivalents, a significant increase from the prior year-end balance of $12.1 million, primarily due to $77.4 million in net cash provided by financing activities from equity offerings. The company's accumulated deficit increased to $326.7 million. No year-over-year comparisons are available from the provided data.
vTv Therapeutics Inc. reported a net loss attributable to the company of $27.0 million for fiscal year 2025, compared to a net loss before noncontrolling interest of $31.1 million. The company generated no revenue during the period. Operating loss was $32.8 million, driven by research and development expenses of $17.9 million and general and administrative expenses of $14.9 million. Other expense net was $136,000, while interest income provided $1.9 million in offset. The net loss per share was $3.00 on both basic and diluted bases, with weighted average shares outstanding of 8.4 million. No prior period comparative figures are provided in the data.
The company reported $0 in revenue for fiscal year 2025. No segment breakdown, geographic mix, or revenue growth drivers are disclosed in the provided financial data. The document shows no revenue from any source during the reporting period.
With $0 revenue and $32.8 million in operating expenses, the company reported an operating loss of $32.8 million for fiscal year 2025. The cost structure consisted primarily of research and development expenses ($17.9 million) and general and administrative expenses ($14.9 million). Share-based compensation expense was $3.8 million. No gross margin or operating margin percentages can be calculated due to the absence of revenue. No prior period margin comparisons are available from the provided data.
Net cash used in operating activities was $25.3 million for fiscal year 2025. The company generated $77.4 million in net cash from financing activities, primarily from the sale of Class A common stock, pre-funded and common warrants. Investing activities had no net cash impact. Cash and cash equivalents increased by $52.2 million to $88.9 million at year-end. Total assets were $89.9 million, with total liabilities of $25.5 million. Stockholders' equity attributable to vTv Therapeutics Inc. was $64.4 million, with accumulated deficit of $326.7 million.
No management guidance, strategic priorities, or specific risk factors are disclosed in the provided financial data. The document contains only financial statement information without forward-looking statements or outlook commentary.